Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072211 | 0.82 | LMNA (0.40) | HTR2CTP53THRBLMNAMAPT | |
| SCHEMBL6072883 | 0.77 | NOTUM (0.46) | HTR2CTP53LMNAMAPTSYK | |
| SCHEMBL6071927 | 0.76 | KDR (0.52) | MAPK14 | |
| SCHEMBL6071883 | 0.70 | KDR (0.51) | MAPK14 | |
| SCHEMBL6072881 | 0.69 | LMNA (0.49) | TP53LMNAMAPTSYKPOLB | |
| SCHEMBL6072495 | 0.68 | SYK (0.57) | TP53LMNAMAPTSYK | |
| SCHEMBL6072249 | 0.67 | HRH3 (0.48) | TP53THRBLMNAMAPK14POLB | |
| SCHEMBL6072414 | 0.67 | KDR (0.52) | MAPK14 | |
| SCHEMBL14792980 | 0.67 | NPC1 (0.53) | HTR2CTP53LMNAMAPTPOLB | |
| SCHEMBL6072151 | 0.66 | RAF1 (0.44) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | ADAMS JERRY L | 2006-10-26 | — | — | US | disclosed |
| EP-1581514-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043379-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | CHKB, MAP3K20, MAP3K6 | HTR2C 1723/4885PARP1 2785/4885TP53 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.